Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled PeriodAnthony A. Portale, Karl Insogna, Peter Kamenický et al.|Calcified Tissue International|2019Cited by 160
FGF-23 Regulates CYP27B1 Transcription in the Kidney and in Extra-Renal TissuesAnkanee Chanakul, Farzana Perwad|PLoS ONE|2013Cited by 80
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extensionKarine Briot, Erik A. Imel, Anthony A. Portale et al.|RMD Open|2021Cited by 72
Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in <i>Hyp</i> miceDaniel Ranch, Farzana Perwad|Journal of Bone and Mineral Research|2011Cited by 68
Chronic Inhibition of ERK1/2 Signaling Improves Disordered Bone and Mineral Metabolism in Hypophosphatemic (Hyp) MiceMartin Y. H. Zhang, Farzana Perwad|Endocrinology|2012Cited by 53